Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about RHHVF
Recent news which mentions RHHVF
< Previous
1
2
3
4
5
Next >
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
October 01, 2021
Tickers
LH
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Benzinga
LH
From
Benzinga
BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial
October 01, 2021
Tickers
BNTX
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHBY
News
From
Benzinga
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
September 30, 2021
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Benzinga
Phase 2 Trial
From
Benzinga
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
September 27, 2021
Tickers
GSK
REGN
RHHBF
RHHBY
Tags
RHHVF
Benzinga
GSK
From
Benzinga
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
Tickers
AMGN
BMY
GILD
MRK
Tags
BMY
General
RHHBF
From
Benzinga
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients
September 24, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Briefs
Health Care
Biotech
From
Benzinga
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
September 24, 2021
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
Biotech
COVID/19 Vaccine
REGN
From
Benzinga
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
September 15, 2021
Tickers
BIIB
RHHBF
RHHBY
RHHVF
Tags
Briefs
BIIB
Biotech
From
Benzinga
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
September 14, 2021
Tickers
NVCR
RHHBF
RHHBY
RHHVF
Tags
Biotech
Market News
RHHBY
From
Benzinga
Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition
September 09, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
M&A
Health Care
Briefs
From
Benzinga
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis
September 08, 2021
Tickers
MGNX
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Small Cap
breast cancer
From
Benzinga
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
September 07, 2021
Tickers
ADAP
RHHBF
RHHBY
RHHVF
Tags
Trading Ideas
Health Care
Briefs
From
Benzinga
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy
September 07, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Briefs
Health Care
Benzinga
From
Benzinga
See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate
August 31, 2021
Tickers
ACIU
RHHBF
RHHBY
RHHVF
Tags
Biotech
RHHBF
General
From
Benzinga
After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US
August 27, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHVF
breast cancer
Benzinga
From
Benzinga
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration
August 24, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
General
RHHBF
Contracts
From
Benzinga
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
August 20, 2021
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHBY
News
From
Benzinga
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
August 17, 2021
Tickers
RHHBF
RHHBY
RHHVF
SNY
Tags
Briefs
Health Care
RHHVF
From
Benzinga
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
August 09, 2021
Tickers
AZN
DSKYF
DSNKY
RHHBF
Tags
Biotech
RHHBY
Market News
From
Benzinga
Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients
August 09, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHBY
Market News
RHHVF
From
Benzinga
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg
August 04, 2021
Tickers
ABCL
PACB
RHHBF
RHHBY
Tags
Benzinga
ABCL
RHHVF
From
Benzinga
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer
August 03, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Briefs
Health Care
Non/Small Cell Lung Cancer
From
Benzinga
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
August 02, 2021
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
General
RHHBF
Market News
From
Benzinga
Roche's Faricimab US Application For Ocular Diseases Under Priority Review
July 29, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
Briefs
RHHVF
From
Benzinga
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings
July 27, 2021
Tickers
BMY
INFI
RHHBF
RHHBY
Tags
Penny Stocks
Biotech
INFI
From
Benzinga
Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters
July 22, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
Briefs
Benzinga
From
Benzinga
Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic
July 22, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Guidance
Biotech
Dividends
From
Benzinga
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
July 21, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
Briefs
RHHVF
From
Benzinga
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
July 21, 2021
Tickers
ABBV
RHHBF
RHHBY
RHHVF
Tags
Biotech
FDA
FDA Breakthrough Designation
From
Benzinga
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
July 19, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
Hemophilia A
RHHBF
General
From
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.